Meta shareholders sue Zuckerberg, Thiel and Sandberg for $8bn over FTC fines

Meta Platforms' current and former leadership, including Mark Zuckerberg, are on trial in Delaware facing an $8 billion shareholder lawsuit alleging illegal user data harvesting in violation of a 2012 FTC agreement, stemming from the Cambridge Analytica scandal. Plaintiffs seek reimbursement for the $5 billion FTC fine and other legal costs in this high-stakes "Caremark" claim, which challenges board oversight and is notoriously difficult to prove but increasingly allowed in Delaware courts. The trial's outcome is significant for corporate governance, especially given recent concerns among companies regarding Delaware's evolving judicial landscape.

Analysis

Meta Platforms' leadership is currently facing an $8 billion shareholder derivative lawsuit centered on a "Caremark" claim, alleging a conscious failure of board oversight related to the Cambridge Analytica data scandal. This suit seeks to hold Mark Zuckerberg and other current and former directors personally liable for reimbursing the company for its $5 billion FTC fine and other associated legal costs. The trial's significance is amplified by its venue in the Delaware Chancery Court, presided over by Chief Judge Kathaleen McCormick, who recently invalidated Elon Musk's $56 billion Tesla pay package, signaling a potential for shareholder-favorable rulings against powerful corporate figures. While the defendants argue they were victims of deceit and had compliance measures in place, the case proceeds amid a tense environment where corporations, including Andreessen Horowitz, are questioning the predictability of Delaware's corporate law, despite recent legislative changes favoring controlling shareholders in other matters. The trial also scrutinizes Zuckerberg's stock sales preceding the scandal's public disclosure, although the defense maintains these were executed under a pre-arranged trading plan. The outcome could set a meaningful precedent for director liability and corporate governance, particularly as Caremark claims, though historically difficult to prove, gain more traction.

Key Decisions for Investors

• Investors should closely monitor the trial's developments for insights into Meta's historical governance practices, as testimony could create significant headline risk and stock volatility.
• The primary risk is not a direct financial hit to Meta's balance sheet, as the lawsuit seeks reimbursement to the company, but rather the potential for a negative verdict to erode confidence in the board's oversight and strategic leadership.
• Consider this lawsuit a key indicator of the evolving legal and regulatory landscape for founder-led tech companies, as the outcome, especially one involving a successful Caremark claim, could signal heightened liability risks for corporate directors nationwide.